Agitation is a common and challenging behavioral symptom in dementia that primary care providers frequently encounter. Characterized by increased motor activity, restlessness, verbal or physical aggression, and emotional distress, agitation affects a large proportion of patients with Alzheimer disease (AD) as the illness progresses. Studies estimate that 30% to 50% of patients with AD experience agitation. For primary care clinicians on the frontlines of dementia care, effectively managing agitation can improve quality of life for patients and caregivers and potentially delay institutionalization.
In a phase 3 randomized controlled trial, escitalopram was not associated with significant improvement in agitation symptoms in patients with Alzheimer dementia and was linked to QT interval prolongation,...
Agitation in patients with Alzheimer disease often appears sudden and puzzling, but in many cases, it is driven by modifiable external or medical factors. Clinicians who can identify these underlying...
Agitation in patients with Alzheimer disease often appears sudden and puzzling, but in many cases, it is driven by modifiable external or medical factors. Clinicians who can identify these underlying...
In a 2024 review, the International Psychogeriatric Association introduces a systematic method to manage agitation in patients with Alzheimer disease. Take our quiz to test your knowledge on this...
A recent study review examined the role of music therapy on quality of life in geriatric populations. Do you know how music therapy can help patients with Alzheimer disease? Take the quiz to test your...
In an interview with Consultant360, Paul B. Rosenberg, MD, discussed his team’s research on using dronabinol, a legal form of synthetic THC, to treat agitation in patients with Alzheimer disease. What...
In this video, Kasia Rothenberg, MD, PhD, describes Alzheimer disease-related agitation, details the difficulty in testing for Alzheimer disease-related agitation, looks ahead to potential treatment options...
In this video, Paul B. Rosenberg, MD, discusses his team’s research on using dronabinol, a legal form of synthetic THC, to treat agitation in patients with Alzheimer disease. The study found that dronabinol...
In this podcast, Leslie Citrome, MD, MPH, talks about resources and strategies of care that caregivers of people with agitation in Alzheimer disease can implement. He talks about how caregivers can be...
In this video, Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C provide the take-home messages from their session “Agitation in Alzheimer’s Dementia: Progress for an Age-Old Problem” at our...
In a small clinical trial, researchers found that patients taking suvorexant, an FDA-approved treatment for insomnia, had reduced levels of amyloid beta (amyloid-β) and tau phosphorylation proteins, which...